FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012435258> ?p ?o ?g. }

• W2012435258 abstract "Background: Indibulin (ZI0-301) is a novel, oral, synthetic small molecule microtubule inhibitor which binds tubulin at a different site than taxanes and vinca alkaloids. Preclinical data demonstrate indibulin does not interact with acetylated (neuronal) tubulins and in clinical studies has not exhibited the neurotoxicity associated with other tubulin binders. Indibulin has potent antitumor activity in human cancer cell lines, including multidrug-, taxane-, and vinblastine-resistant. Norton-Simon modeling based on cell line data suggested that dose dense (dd) administration could optimize efficacy while limiting toxicity. Methods: Eligible patients (pts) have metastatic or unresectable locally advanced breast cancer, ECOG performance status ≤ 2, adequate organ function, measurable or nonmeasurable disease and any number of prior therapies. Uncontrolled gastrointestinal malabsorption syndrome and grade 2 or higher peripheral neuropathy are the principal exclusions. Adverse events (AEs) are graded by CTCAE v. 4.0. Objective disease status is evaluated according to RECIST 1.1. The primary objective of the phase (Ph) I portion of the study is to determine the maximum tolerated dose (MTD) of indibulin when given in dd fashion 5 days treatment, 9 days rest using standard 3+3 dose escalation schema. The secondary objectives are to evaluate safety profile at various dosing levels, pharmacokinetics (PK) and preliminary activity of indibulin. Once the MTD is defined, a food effect cross- over group (N = 12) will be enrolled. Two groups of 6 pts each will be treated in either the fed or fasted state during the first cycle. A subgroup of 13 pts consisting of 12 pts from the food effect group plus the last pt from the MTD cohort will be evaluated for PFS at 4 months and will serve as the population for the first stage of a Simon two-stage design. If 4 or more out of 13 pts do not progress at 4 months, the Ph II portion of the study will be opened. Results: Twenty one pts (20 F, 1 M) have been enrolled to cohorts 1 through 6 and the dose escalation is ongoing. Preliminary safety and efficacy data have been analyzed for 18 pts treated in cohorts 1 through 5 and are presented henceforth. No DLT has been observed and no MTD has been reached. Median age 58 years (32–81). PS 0=4, 1=12, 2=2. Median number of prior therapies 5 (1–12). Most frequent treatment-emergent AEs were: anorexia, constipation, cough, nausea (each in 39% pts); dyspnea (33%); fatigue, vomiting (each 28%). There were no related grade 3–4 AEs. PK analysis revealed that indibulin plasma exposures increased approximately dose proportionally from 25 to 200 mg with C max of 165 ± 89 ng/mL and AUC 0-24 of 1411 ± 111 ng·h/mL at 200 mg. There were no objective responses. Stable disease was seen in 1 pt in the 150 mg cohort. Longest duration on-study was 4 months. Conclusions: Oral indibulin was well tolerated in the doses up to 200 mg and the dose-proportional PK with lack of DLTs allows for further dose-escalation. Stable disease observed at sub-MTD dose may be a sign of activity in this heavily pre-treated population. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-11-10." @default.
• W2012435258 created "2016-06-24" @default.
• W2012435258 creator A5000194388 @default.
• W2012435258 creator A5000343593 @default.
• W2012435258 creator A5001684666 @default.
• W2012435258 creator A5006700202 @default.
• W2012435258 creator A5008865840 @default.
• W2012435258 creator A5019910948 @default.
• W2012435258 creator A5020083811 @default.
• W2012435258 creator A5039890117 @default.
• W2012435258 creator A5043654587 @default.
• W2012435258 creator A5065694446 @default.
• W2012435258 creator A5068005136 @default.
• W2012435258 creator A5072793088 @default.
• W2012435258 creator A5085111210 @default.
• W2012435258 creator A5086879427 @default.
• W2012435258 date "2012-12-15" @default.
• W2012435258 modified "2023-09-27" @default.
• W2012435258 title "Abstract P6-11-10: IBL2001: Phase I/II study of a novel dose-dense schedule of oral indibulin for the treatment of metastastic breast cancer." @default.
• W2012435258 doi "https://doi.org/10.1158/0008-5472.sabcs12-p6-11-10" @default.
• W2012435258 hasPublicationYear "2012" @default.
• W2012435258 type Work @default.
• W2012435258 sameAs 2012435258 @default.
• W2012435258 citedByCount "0" @default.
• W2012435258 crossrefType "proceedings-article" @default.
• W2012435258 hasAuthorship W2012435258A5000194388 @default.
• W2012435258 hasAuthorship W2012435258A5000343593 @default.
• W2012435258 hasAuthorship W2012435258A5001684666 @default.
• W2012435258 hasAuthorship W2012435258A5006700202 @default.
• W2012435258 hasAuthorship W2012435258A5008865840 @default.
• W2012435258 hasAuthorship W2012435258A5019910948 @default.
• W2012435258 hasAuthorship W2012435258A5020083811 @default.
• W2012435258 hasAuthorship W2012435258A5039890117 @default.
• W2012435258 hasAuthorship W2012435258A5043654587 @default.
• W2012435258 hasAuthorship W2012435258A5065694446 @default.
• W2012435258 hasAuthorship W2012435258A5068005136 @default.
• W2012435258 hasAuthorship W2012435258A5072793088 @default.
• W2012435258 hasAuthorship W2012435258A5085111210 @default.
• W2012435258 hasAuthorship W2012435258A5086879427 @default.
• W2012435258 hasConcept C112705442 @default.
• W2012435258 hasConcept C121608353 @default.
• W2012435258 hasConcept C126322002 @default.
• W2012435258 hasConcept C143998085 @default.
• W2012435258 hasConcept C197934379 @default.
• W2012435258 hasConcept C2777096885 @default.
• W2012435258 hasConcept C2777288759 @default.
• W2012435258 hasConcept C2777292972 @default.
• W2012435258 hasConcept C2777511904 @default.
• W2012435258 hasConcept C29730261 @default.
• W2012435258 hasConcept C530470458 @default.
• W2012435258 hasConcept C71924100 @default.
• W2012435258 hasConcept C90924648 @default.
• W2012435258 hasConcept C98274493 @default.
• W2012435258 hasConceptScore W2012435258C112705442 @default.
• W2012435258 hasConceptScore W2012435258C121608353 @default.
• W2012435258 hasConceptScore W2012435258C126322002 @default.
• W2012435258 hasConceptScore W2012435258C143998085 @default.
• W2012435258 hasConceptScore W2012435258C197934379 @default.
• W2012435258 hasConceptScore W2012435258C2777096885 @default.
• W2012435258 hasConceptScore W2012435258C2777288759 @default.
• W2012435258 hasConceptScore W2012435258C2777292972 @default.
• W2012435258 hasConceptScore W2012435258C2777511904 @default.
• W2012435258 hasConceptScore W2012435258C29730261 @default.
• W2012435258 hasConceptScore W2012435258C530470458 @default.
• W2012435258 hasConceptScore W2012435258C71924100 @default.
• W2012435258 hasConceptScore W2012435258C90924648 @default.
• W2012435258 hasConceptScore W2012435258C98274493 @default.
• W2012435258 hasLocation W20124352581 @default.
• W2012435258 hasOpenAccess W2012435258 @default.
• W2012435258 hasPrimaryLocation W20124352581 @default.
• W2012435258 hasRelatedWork W1601278343 @default.
• W2012435258 hasRelatedWork W1965679184 @default.
• W2012435258 hasRelatedWork W1975672316 @default.
• W2012435258 hasRelatedWork W1979753180 @default.
• W2012435258 hasRelatedWork W2013294240 @default.
• W2012435258 hasRelatedWork W2037927419 @default.
• W2012435258 hasRelatedWork W2043324920 @default.
• W2012435258 hasRelatedWork W2045058534 @default.
• W2012435258 hasRelatedWork W2069619048 @default.
• W2012435258 hasRelatedWork W2073378249 @default.
• W2012435258 hasRelatedWork W2079571738 @default.
• W2012435258 hasRelatedWork W2148325053 @default.
• W2012435258 hasRelatedWork W2161576352 @default.
• W2012435258 hasRelatedWork W2247131005 @default.
• W2012435258 hasRelatedWork W2287961714 @default.
• W2012435258 hasRelatedWork W2323783599 @default.
• W2012435258 hasRelatedWork W2477879802 @default.
• W2012435258 hasRelatedWork W2560857104 @default.
• W2012435258 hasRelatedWork W2755102164 @default.
• W2012435258 hasRelatedWork W3154567952 @default.
• W2012435258 isParatext "false" @default.
• W2012435258 isRetracted "false" @default.
• W2012435258 magId "2012435258" @default.
• W2012435258 workType "article" @default.